skip to Main Content

Moving from pre-clinical to clinical-stage

IBT CEO Dr. M. Javad Aman will discuss the development of a multi-component toxoid vaccine for S. aureus and the regulatory challenges and opportunities when moving a product from pre-clinical to clinical stage. The live webinar scheduled for Sept. 24, 2020 will feature experts on various aspects of antimicrobial resistance (AMR) who will share their knowledge and opinions the current state of the AMR R&D field.

Register for Live Webinar Sept. 24, 2020 9:30-11:30AM

Back To Top
×Close search
Search

IBT Bioservices continues to conduct critical work as an essential business under the State of Maryland’s COVID-19 response directive. We have implemented a risk management plan and are continually monitoring the situation to ensure continuation of research according to public health services recommended best-practices for keeping our employees and the community safe. 

The IBT Bioservices team will continue to deliver high quality products and services for every project. If you have any questions contact us at Services@IBTBioservices.com